Medical management of thyroid eye disease: Current concepts and emerging therapies

Thyroid eye disease (TED), also known as Graves’ ophthalmopathy or thyroid-associated orbitopathy (TAO), is the most common cause of both unilateral and bilateral proptosis in adults. It is an autoimmune inflammatory disorder affecting the periorbital and orbital tissues, leading to a wide spectrum of heterogeneous clinical manifestations that can significantly impair quality of life and, in severe cases, threaten vision. The medical management of TED has evolved considerably over the past decade. Systemic corticosteroids remain the first-line therapy for controlling active inflammation. However, the landmark approval of teprotumumab—a human monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R)—by the U.S. Food and Drug Administration (FDA) in 2020 has transformed the therapeutic landscape. This advancement has ushered in a new era of targeted therapy for TED. This review summarizes the pathophysiology and clinical activity of TED and outlines a comprehensive framework for its medical management, encompassing both conventional treatments and emerging therapeutic approaches. J. Natl.Inst. Ophthalmol.2025;8(2): 63-68

Authors

Publication Details

Journal
Journal of National Institute of Ophthalmology
Published
2026-11-19
DOI
https://doi.org/10.3329/jnio.v8i2.95173
Primary Topic
Ophthalmology and Eye Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Medical management of thyroid eye disease: Current concepts and emerging therapies

Murtuza Nuruddin
Journal of National Institute of Ophthalmology
Ophthalmology and Eye Disorders
article

Medical management of thyroid eye disease: Current concepts and emerging therapies

Murtuza Nuruddin
article en

Abstract

Thyroid eye disease (TED), also known as Graves’ ophthalmopathy or thyroid-associated orbitopathy (TAO), is the most common cause of both unilateral and bilateral proptosis in adults. It is an autoimmune inflammatory disorder affecting the periorbital and orbital tissues, leading to a wide spectrum of heterogeneous clinical manifestations that can significantly impair quality of life and, in severe cases, threaten vision. The medical management of TED has evolved considerably over the past decade. Systemic corticosteroids remain the first-line therapy for controlling active inflammation. However, the landmark approval of teprotumumab—a human monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R)—by the U.S. Food and Drug Administration (FDA) in 2020 has transformed the therapeutic landscape. This advancement has ushered in a new era of targeted therapy for TED. This review summarizes the pathophysiology and clinical activity of TED and outlines a comprehensive framework for its medical management, encompassing both conventional treatments and emerging therapeutic approaches. J. Natl.Inst. Ophthalmol.2025;8(2): 63-68

Journal of National Institute of OphthalmologyVol. 8(2)
Ophthalmology and Eye Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon